PDCD1 and hepatocellular carcinoma: Therefore, we designed this retrospective study to compare the survival of patients with advanced HCC who received HAIC combined with lenvatinib plus PD-1 inhibitors (HPL) versus those who received lenvatinib plus PD-1 inhibitors (PL), aiming to provide a reference for the treatment of advanced HCC.